Dr. Alavi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2800 W Grand Blvd
Karmanos Cancer Center
Detroit, MI 48202Phone+1 818-364-3205- Is this information wrong?
Education & Training
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2013 - 2014- University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2012 - 2013
Olive View/UCLA Medical CenterResidency, Internal Medicine, 2008 - 2011
O'Connor HospitalInternship, Transitional Year, 2007 - 2008
University of Michigan Medical SchoolClass of 2007- University of California, BerkeleyB.A., Molecular and Cell Biology, 1998 - 2002
Certifications & Licensure
CA State Medical License 2009 - Present
MI State Medical License 2015 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Commendation for Excellence in Medical Student Teaching UCLA Ronald Reagan Medical Center, 2009
Clinical Trials
- Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT Start of enrollment: 2020 Feb 20
- Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma Start of enrollment: 2020 Aug 17
Publications & Presentations
PubMed
- 6 citationsThree-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow D...Bronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, Brent R Logan, Farhad Khimani, Brian C Shaffer, Nirav N Shah, Alisha Mussetter, Xiao-Ying Tang, John M M...> ;Transplantation and Cellular Therapy. 2023 Mar 1
- Role of High-Dose Adjuvant Chemotherapy Followed by Autologous Stem Cell Transplantation in Locally Advanced Triple-Negative Breast Cancer: A Retrospective Chart Review.Bayan Al-Share, Hadeel Assad, Judith Abrams, Abhinav Deol, Asif Alavi, Dipenkumar Modi, Andrew Kin, Voravit Ratanatharathorn, Joseph Uberti, Lois Ayash> ;Journal of Oncology. 2022 Jan 1
- 5 citationsImproved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents.Harsh Shah, Hyejeong Jang, Paramveer Singh, Jorgena Kosti, Andrew Kin, Asif Alavi, Voravit Ratanatharathorn, Lois Ayash, Joseph P. Uberti, Radhakrishnan Ramchandren, S...> ;Leukemia & Lymphoma. 2021 Nov 15
- Join now to see all
Journal Articles
- Minimal residual disease as a predictive factor for relapse after allogeneic hematopoietic stem Cell transplant in adult patients with acute myeloid leukemia in first ...Grubovikj RM, Alavi A, Koppel A, Territo M, Schiller GJ, Cancers, 1/1/2012
- Tumor suppressor and T-regulatory functions of Foxp3 are mediated through separate signaling pathwaysHeinze E, Chan G, Mory R, Khavari R, Alavi A, Chung SY, Nishimura RN, Weisbart RH, Oncology Letters, 1/1/2011
Abstracts/Posters
- Absolute Lymphocyte Count (ALC) Less Than 100 Predicts Adverse Transplant Outcomes with Rabbit Thymoglobulin in Patients Undergoing Matched Unrelated Allogeneic Hemato...Asif Alavi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Use of Thymoglobulin with Lower Dose of Busulfan Results in Less Acute Gvhd Following Unrelated Donor Allogeneic Stem Cell Transplantation for AML without Affecting Re...Asif Alavi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Maintenance Therapy after Second Autologous Stem Cell Transplant in Multiple Myeloma Improves Overall SurvivalAsif Alavi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Haploidentical Stem Cell Transplantation at USCCenter for the Study of Blood Diseases, University of Southern California, Los Angeles, CA - 1/22/2015
- Blastic Plasmacytoid Dendritic Cell NeoplamCenter for the Study of Blood Diseases, University of Southern California, Los Angeles, CA - 1/28/2013
- How should we manage a patient with Stage IV DLBCL non-GC type?Los Angeles, CA - 1/20/2013
Press Mentions
School Celebrates Faculty Promotions, Tenure and Awards Sept. 29September 8th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
